Get the Stockscreener App
10.00
0.00%
0.00
Envveno Medical Corp stock is traded at $10.00, with a volume of 32,244.
It is up +0.00% in the last 24 hours and up +1.94% over the past month.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$10.00
Open:
$10.215
24h Volume:
32,244
Relative Volume:
2.50
Market Cap:
$6.68M
Revenue:
-
Net Income/Loss:
$-18.82M
P/E Ratio:
-0.3206
EPS:
-31.1883
Net Cash Flow:
$-14.79M
1W Performance:
-2.06%
1M Performance:
+1.94%
6M Performance:
-9.01%
1Y Performance:
-93.42%
1-Day Range:
$9.98
$10.99
1-Week Range:
$9.73
$10.99
52-Week Range:
$8.67
$196.70
Envveno Medical Corp Stock (NVNO) Company Profile
Name
Envveno Medical Corp
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
10.00 | 6.68M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp Stock (NVNO) Latest News
Insider Selling: Francis Duhay Sells Shares of enVVeno Medical C - GuruFocus
Director at enVVeno Medical (NASDAQ: NVNO) sells 140 shares under Rule 10b5-1 plan - Stock Titan
[144] enVVeno Medical Corp SEC Filing - Stock Titan
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System - PhillyBurbs
enVVeno Medical Announces Reverse Stock Split - Great Falls Tribune
enVVeno Medical (NVNO) Holds Steady at $10.75 – Support and Resistance Define Neutral RangeUndervalued Stocks - newsline.com
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series - marketscreener.com
First FDA IDE venous valve study: enVVeno CEO Q&A June 9 - Stock Titan
enVVeno Medical (NVNO) Edges Higher as Stock Tests Key Resistance Near $11.90Throwback Trade - The Legal Advocate
enVVeno Medical (NVNO) Edges Lower as Stock Holds Above Key SupportFRAMA Signal - newsline.com
enVVeno Medical (NVNO) Slips 1.03% as Price Hovers Near Key Support at $10.47Factor Crowding - newsline.com
NVNO Q3 2025 Earnings: Narrower Net Loss Surpasses Analyst ExpectationsEarnings Season Review - The Legal Advocate
This Tiny Medical-Device Stock Is Back Above $11. Its Next FDA Test Is the Whole Trade - Bez Kabli
enVVeno Medical Q3 2025 Earnings: Narrower Loss Beats Expectations as Clinical Programs AdvanceProfit Margin Analysis - The Legal Advocate
enVVeno Medical (NVNO) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Progress - newsline.com
enVVeno Medical (NVNO) Edges Higher: Analyzing Recent Price Action and Key LevelsWave Truncation - Newser
Perceptive entities disclose 9.99% stake in enVVeno (NASDAQ: NVNO) - Stock Titan
This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It? - MSN
Kingdon group holds 36,166 shares in enVVeno (NASDAQ: NVNO) - Stock Titan
Number of shareholders of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment - The Joplin Globe
First-ever U.S. venous valve trial could address DVI in 3M Americans - Stock Titan
enVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor What This Means Segment - FinanzNachrichten.de
TradingKey - TradingKey
What enVVeno (NVNO) is doing that smart investors recognize (-2.26%) 2026-05-08Stock Surge - Newser
enVVeno Medical sees cash runway into 3Q27 - TipRanks
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter - TipRanks
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year - TipRanks
enVVeno Reports Having $25M Cash on Hand in Q1 Earnings - Orange County Business Journal
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System - IndyStar
With $25M on hand, enVVeno moves toward first U.S. venous valve study - Stock Titan
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
enVVeno Medical (NVNO) trims Q1 loss and secures FDA IDE for pivotal enVVe TAVVE study - Stock Titan
One enVVeno Medical Insider Raised Their Stake In The Previous Year - Yahoo Finance
enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve - MedTech Intelligence
enVVeno Medical secures FDA IDE approval for venous valve study - Medical Device Network
enVVeno Medical (NVNO) Secures FDA IDE Approval for Pivotal Stud - GuruFocus
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study - TipRanks
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve - BioSpace
enVVeno Medical Wins FDA IDE for TAVVE Trial - TipRanks
enVVeno receives FDA approval for venous valve pivotal trial By Investing.com - Investing.com South Africa
enVVeno receives FDA approval for venous valve pivotal trial - Investing.com
FDA clears enVVeno (NASDAQ: NVNO) pivotal enVVe CVI valve study - Stock Titan
FDA allows first U.S. study of a nonsurgical vein valve for 3M patients - Stock Titan
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - Times Reporter
Envveno Medical Corp Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):